Shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE – Get a rating) received a consensus “moderate buy” recommendation from the ten rating agencies that currently cover the company, reports Marketbeat Ratings. One financial analyst gave the stock a sell rating and seven issued a buy rating for the company. The 12-month average price target among analysts who have reported on the stock in the past year is $47.43.
A number of research companies have recently published reports on XENE. StockNews.com upgraded Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a Wednesday, September 7 research report. Bank of America began covering Xenon Pharmaceuticals in a research report on Monday, August 29. They set a “buy” rating and a price target of $45.00 for the company. JPMorgan Chase & Co. began covering Xenon Pharmaceuticals in a research report on Thursday, July 21. They set an “overweight” rating and a price target of $55.00 for the company. SVB Leerink raised its price target on Xenon Pharmaceuticals from $40.00 to $46.00 and gave the company an “outperform” rating in a Thursday, August 11 research report. Finally, Wedbush raised its target price on Xenon Pharmaceuticals from $41.00 to $50.00 in a Wednesday, August 10 report.
Stock Xenon Pharmaceuticals down 5.1%
Shares of Xenon Pharmaceuticals opened at $37.31 on Monday. The stock has a market capitalization of $2.32 billion, a PE ratio of -20.39 and a beta of 1.47. The company has a fifty-day simple moving average of $36.25 and a 200-day simple moving average of $32.45. Xenon Pharmaceuticals has a 12-month low of $14.65 and a 12-month high of $41.39.
Xenon Pharmaceuticals (NASDAQ: XENE- Get a rating) last reported results on Tuesday, August 9. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The company posted revenue of $0.54 million in the quarter, versus analyst estimates of $3.25 million. Xenon Pharmaceuticals had a negative return on equity of 17.33% and a negative net margin of 432.24%. The company’s quarterly revenue was down 75.8% year over year. During the same period last year, the company achieved EPS of ($0.51). Analysts expect Xenon Pharmaceuticals to post EPS of -2.05 for the current fiscal year.
Insider Trading at Xenon Pharmaceuticals
In other news, Executive Vice President James R. Empfield sold 57,743 shares of Xenon Pharmaceuticals in a trade dated Friday, August 12. The stock was sold at an average price of $38.31, for a total value of $2,212,134.33. Following the transaction, the executive vice president now directly owns 10,000 shares of the company, valued at $383,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, available at the SEC website. Separately, Executive Vice President James R. Empfield sold 57,743 shares of Xenon Pharmaceuticals in a trade dated Friday, August 12. The stock was sold at an average price of $38.31, for a total transaction of $2,212,134.33. Following the sale, the executive vice president now directly owns 10,000 shares of the company, valued at $383,100. The transaction was disclosed in a document filed with the SEC, accessible via this link. Also, director Simon N. Pimstone sold 33,942 shares of Xenon Pharmaceuticals in a trade dated Monday, August 15. The stock was sold at an average price of $37.76, for a total value of $1,281,649.92. Following the sale, the administrator now directly owns 58,058 shares of the company, valued at $2,192,270.08. Disclosure of this sale can be found here. In the past ninety days, insiders have sold 182,820 shares of the company worth $6,982,432. Insiders of the company hold 6.06% of the shares of the company.
Institutional investors weigh in on Xenon Pharmaceuticals
A number of institutional investors have recently increased or reduced their stake in the company. BNP Paribas Arbitrage SA increased its stake in Xenon Pharmaceuticals by 1,567.5% during the first quarter. BNP Paribas Arbitrage SA now owns 1,334 shares of the biopharmaceutical company valued at $41,000 after buying an additional 1,254 shares last quarter. Advisors Asset Management Inc. acquired a new stake in Xenon Pharmaceuticals during the first quarter valued at approximately $66,000. UBS Group AG increased its stake in Xenon Pharmaceuticals by 102.1% during the second quarter. UBS Group AG now owns 2,472 shares of the biopharmaceutical company valued at $76,000 after buying an additional 1,249 shares last quarter. JPMorgan Chase & Co. increased its stake in Xenon Pharmaceuticals by 33.4% in the first quarter. JPMorgan Chase & Co. now owns 6,371 shares of the biopharmaceutical company valued at $194,000 after buying 1,596 additional shares last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Xenon Pharmaceuticals during the second quarter valued at approximately $223,000. 91.64% of the shares are held by institutional investors and hedge funds.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, is engaged in the development of therapeutic products to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener which is a Phase III clinical trial for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in a phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Featured articles
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Xenon Pharmaceuticals was not on the list.
While Xenon Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here
